27 years of historical data (1999–2025) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sanofi trades at 20.3x earnings, roughly in line with its 5-year average of 20.9x, sitting at the 33rd percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 14%. On a free-cash-flow basis, the stock trades at 11.2x P/FCF, 28% below the 5-year average of 15.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $117.5B | $118.3B | $120.7B | $125.0B | $121.3B | $125.5B | $121.8B | $125.5B | $108.3B | $108.1B | $104.1B |
| Enterprise Value | $134.2B | $132.4B | $131.2B | $134.9B | $129.7B | $137.8B | $131.6B | $141.7B | $126.0B | $113.4B | $112.4B |
| P/E Ratio → | 20.32 | 23.87 | 22.02 | 23.13 | 15.23 | 20.12 | 9.90 | 44.04 | 25.09 | 12.80 | 22.10 |
| P/S Ratio | 2.13 | 2.53 | 2.73 | 3.00 | 2.99 | 3.20 | 3.26 | 3.33 | 3.03 | 2.98 | 3.00 |
| P/B Ratio | 1.40 | 1.65 | 1.55 | 1.68 | 1.61 | 1.82 | 1.93 | 2.12 | 1.83 | 1.86 | 1.80 |
| P/FCF | 11.21 | 13.30 | 20.51 | 14.46 | 14.57 | 14.80 | 22.84 | 21.17 | 30.33 | 19.93 | 18.08 |
| P/OCF | 9.27 | 11.00 | 13.29 | 12.18 | 11.52 | 11.93 | 16.35 | 16.20 | 19.52 | 14.65 | 13.28 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Sanofi's enterprise value stands at 11.9x EBITDA, roughly in line with its 5-year average of 11.9x. The Healthcare sector median is 13.8x, placing the stock at a 14% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.83 | 2.96 | 3.24 | 3.20 | 3.52 | 3.52 | 3.77 | 3.53 | 3.13 | 3.24 |
| EV / EBITDA | 11.91 | 13.86 | 12.10 | 11.85 | 9.78 | 12.01 | 7.40 | 13.50 | 14.07 | 11.95 | 11.43 |
| EV / EBIT | 17.93 | 13.98 | 17.61 | 19.39 | 12.47 | 16.83 | 9.26 | 44.04 | 25.71 | 19.05 | 17.03 |
| EV / FCF | — | 14.89 | 22.29 | 15.62 | 15.58 | 16.25 | 24.66 | 23.90 | 35.29 | 20.91 | 19.52 |
Margins and return-on-capital ratios measuring operating efficiency
Sanofi earns an operating margin of 13.6%. Operating margins have compressed from 16.7% to 13.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 10.4% is modest. ROIC of 5.5% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3% | 72.3% | 70.2% | 69.7% | 70.7% | 68.7% | 67.5% | 68.2% | 67.9% | 67.9% | 69.2% |
| Operating Margin | 13.6% | 13.6% | 16.4% | 16.7% | 25.1% | 20.7% | 37.8% | 8.1% | 13.1% | 16.0% | 18.8% |
| Net Profit Margin | 16.7% | 16.7% | 12.6% | 13.0% | 20.6% | 15.9% | 32.9% | 7.3% | 12.1% | 23.2% | 13.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.4% | 10.4% | 7.3% | 7.2% | 11.6% | 9.4% | 20.1% | 4.7% | 7.3% | 14.5% | 8.1% |
| ROA | 6.0% | 6.0% | 4.3% | 4.3% | 6.8% | 5.3% | 10.8% | 2.5% | 4.1% | 8.2% | 4.5% |
| ROIC | 5.5% | 5.5% | 6.3% | 6.2% | 9.2% | 7.9% | 14.3% | 3.0% | 5.0% | 6.7% | 7.4% |
| ROCE | 6.3% | 6.3% | 7.0% | 6.8% | 10.1% | 8.4% | 15.1% | 3.3% | 5.2% | 6.7% | 7.5% |
Solvency and debt-coverage ratios — lower is generally safer
Sanofi carries a Debt/EBITDA ratio of 2.3x, which is manageable (27% below the sector average of 3.1x). Net debt stands at $14.1B ($21.8B total debt minus $7.7B cash). Interest coverage of 11.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | 0.23 | 0.25 | 0.28 | 0.32 | 0.37 | 0.44 | 0.42 | 0.27 | 0.32 |
| Debt / EBITDA | 2.28 | 2.28 | 1.65 | 1.64 | 1.60 | 1.95 | 1.33 | 2.47 | 2.75 | 1.64 | 1.89 |
| Net Debt / Equity | — | 0.20 | 0.13 | 0.13 | 0.11 | 0.18 | 0.15 | 0.27 | 0.30 | 0.09 | 0.14 |
| Net Debt / EBITDA | 1.48 | 1.48 | 0.97 | 0.88 | 0.64 | 1.07 | 0.55 | 1.54 | 1.98 | 0.56 | 0.84 |
| Debt / FCF | — | 1.59 | 1.78 | 1.16 | 1.02 | 1.45 | 1.83 | 2.73 | 4.96 | 0.97 | 1.44 |
| Interest Coverage | 11.73 | 11.73 | 11.65 | 13.57 | 26.41 | 21.53 | 32.76 | 5.69 | 9.61 | 17.41 | 16.35 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.09x means Sanofi can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.29x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.27x to 1.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | 1.09 | 1.46 | 1.27 | 1.42 | 1.44 | 1.75 | 1.40 | 1.41 | 1.70 | 1.62 |
| Quick Ratio | 0.29 | 0.29 | 1.14 | 0.87 | 1.05 | 1.03 | 1.32 | 1.01 | 0.98 | 1.26 | 1.20 |
| Cash Ratio | 0.27 | 0.27 | 0.27 | 0.36 | 0.53 | 0.47 | 0.72 | 0.48 | 0.40 | 0.67 | 0.63 |
| Asset Turnover | — | 0.37 | 0.33 | 0.33 | 0.32 | 0.33 | 0.33 | 0.33 | 0.32 | 0.36 | 0.33 |
| Inventory Turnover | 0.57 | 0.57 | 1.40 | 1.31 | 1.33 | 1.41 | 1.46 | 1.50 | 1.53 | 1.70 | 1.55 |
| Days Sales Outstanding | — | 3.10 | 87.60 | 96.82 | 96.70 | 91.19 | 97.22 | 97.80 | 95.61 | 87.42 | 95.21 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sanofi does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 4.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 3.9% | 3.6% | 3.4% | 3.2% | 3.2% | 3.1% | 3.5% | 3.4% | 3.6% |
| Payout Ratio | — | — | 84.6% | 82.5% | 49.8% | 64.4% | 32.0% | 139.2% | 87.6% | 44.1% | 79.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.9% | 4.2% | 4.5% | 4.3% | 6.6% | 5.0% | 10.1% | 2.3% | 4.0% | 7.8% | 4.5% |
| FCF Yield | 8.9% | 7.5% | 4.9% | 6.9% | 6.9% | 6.8% | 4.4% | 4.7% | 3.3% | 5.0% | 5.5% |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.5% | 0.4% | 0.3% | 0.7% | 0.0% | 1.0% | 2.0% | 2.8% |
| Total Shareholder Yield | 0.0% | 0.0% | 4.1% | 4.0% | 3.8% | 3.5% | 3.9% | 3.1% | 4.5% | 5.4% | 6.4% |
| Shares Outstanding | — | $2.4B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.5B | $2.6B |
Compare SNY with 4 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SNYYou | $118B | 20.3 | 11.9 | 11.2 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
| MRK | $307B | 17.0 | 9.9 | — | 81.5% | 41.2% | 37.1% | 32.6% | — |
| PFE | $157B | 20.3 | 7.7 | — | 70.3% | 24.7% | 8.6% | 9.4% | — |
| GSK | $119B | 16.2 | 9.6 | 15.1 | 72.5% | 21.9% | 38.5% | 18.6% | 1.7 |
| GRFS | $2B | 33.5 | 6.8 | 3.8 | 38.7% | 16.5% | 1.9% | 5.0% | 6.2 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 27 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SNY stacks up against sector leader Merck & Co., Inc..
Start ComparisonSanofi's current P/E ratio is 20.3x. The historical average is 24.7x. This places it at the 33th percentile of its historical range.
Sanofi's current EV/EBITDA is 11.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.0x.
Sanofi's return on equity (ROE) is 10.4%. The historical average is 12.7%.
Based on historical data, Sanofi is trading at a P/E of 20.3x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sanofi has 72.3% gross margin and 13.6% operating margin. Operating margin between 10-20% is typical for established companies.
Sanofi's Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.